Friday 20 March 2026
Internal Reference Number: FOI_9208
Date Request Received: 04/02/2026 00:00:00
Date Request Replied To: 27/02/2026 00:00:00
This response was sent via: By Email
Request Summary: Oncology Breast Cancer
Request Category: Researcher
| Question Number 1: I am researching the incidence and treatment of breast cancer. Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Abemaciclib + Fulvestrant • Alpelisib + Fulvestrant • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide only • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel • Atezolizumab • Capivasertib • Capecitabine as a single agent • Carboplatin + Paclitaxel • Elacestrant • Eribulin as a single agent or in combination • Everolimus + Exemestane • Fulvestrant as a single agent • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Palbociclib + Fulvestrant • Parp Inhibitors (Olaparib/Talazoparib) • Pembrolizumab Monotherapy • Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide • Carboplatin + Paclitaxel + Pembrolizumab • Pertuzumab (Perjeta) + Trastuzumab (Herceptin) • Phesgo (Pertuzumab + Trastuzumab in a single injection) • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Ribociclib + Fulvestrant • Sacituzumab Govitecan • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent • Trastuzumab deruxtecan (Enhertu) • Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel • Trastuzumab emtansine (Kadcyla) • Any other active systemic anti-cancer therapy | |
| Answer To Question 1: Please see attached document To accompany this answer to question 1 please also see the documents listed below:  FOI 9208 Q1 & 2.pdf | |
| Question Number 2: In the past 3 months, how many patients have been treated with the following systemic anti-cancer therapies for breast cancer (please indicate whether they were treated for early or metastatic disease): Please see table provided | |
| Answer To Question 2: Please see attached | |
| Question Number 3: Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part. | |
| Answer To Question 3: The Trust is currently participating in 3 Clinical Trials for breast cancer. All 3 are closed to participant recruitment but have participants in follow up. FAST-Forward: 21 participants recruited. MAMMO-50: 64 participants recruited. OPTIMA: 48 participants recruited. | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
